Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2010 Mar 27

PMID 20337577

Citations 53

Authors

Latanya M Scott

Harshani R Lawrence

Said M Sebti

Nicholas J Lawrence

Jie Wu

Affiliations

Soon will be listed here.

Abstract

Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.

Citing Articles

Targeting Shp2 as a therapeutic strategy for neurodegenerative diseases.

Pang J, Cen C, Tian Y, Cao X, Hao L, Tao X Transl Psychiatry. 2025; 15(1):6.

PMID: 39794316 PMC: 11724000. DOI: 10.1038/s41398-024-03222-1.

EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling.

Hu Z, Chen P, Li W, Krone M, Zheng S, Saarbach J Sci Adv. 2024; 10(13):eadj7251.

PMID: 38536914 PMC: 10971414. DOI: 10.1126/sciadv.adj7251.

Setting sail: Maneuvering SHP2 activity and its effects in cancer.

Welsh C, Allen S, Madan L Adv Cancer Res. 2023; 160:17-60.

PMID: 37704288 PMC: 10500121. DOI: 10.1016/bs.acr.2023.03.003.

PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.

Kelm J, Pandey D, Malin E, Kansou H, Arora S, Kumar R Mol Cancer. 2023; 22(1):62.

PMID: 36991452 PMC: 10061819. DOI: 10.1186/s12943-022-01707-5.

From Stem to Sternum: The Role of Shp2 in the Skeleton.

Jensen N, Kelly R, Kelly K, Khoo S, Sidles S, LaRue A Calcif Tissue Int. 2022; 112(4):403-421.

PMID: 36422682 DOI: 10.1007/s00223-022-01042-3.

References

Lee S, Liang F, Guo X, Xie L, Cahill S, Blumenstein M . Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angew Chem Int Ed Engl. 2005; 44(27):4242-4. DOI: 10.1002/anie.200462004. View

Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, Ekiel I . Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem. 2004; 279(12):11882-9. DOI: 10.1074/jbc.M312905200. View

Dawson M, Xia Z, Jiang T, Ye M, Fontana J, Farhana L . Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell.... J Med Chem. 2008; 51(18):5650-62. PMC: 4097887. DOI: 10.1021/jm800456k. View

Qian Y, Chan A, Madhavan R, Peng H . The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters. BMC Neurosci. 2008; 9:70. PMC: 2490698. DOI: 10.1186/1471-2202-9-70. View

Esteban V, Vazquez-Novelle M, Calvo E, Bueno A, Sacristan M . Human Cdc14A reverses CDK1 phosphorylation of Cdc25A on serines 115 and 320. Cell Cycle. 2006; 5(24):2894-8. DOI: 10.4161/cc.5.24.3566. View

Ray D, Terao Y, Fuhrken P, Ma Z, DeMayo F, Christov K . Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007; 67(3):984-91. DOI: 10.1158/0008-5472.CAN-06-3927. View

Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L . Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. Pathol Oncol Res. 2009; 15(4):555-60. DOI: 10.1007/s12253-009-9153-1. View

Zhang Z, Lin S, Neel B, Haimovich B . Phosphorylated alpha-actinin and protein-tyrosine phosphatase 1B coregulate the disassembly of the focal adhesion kinase x Src complex and promote cell migration. J Biol Chem. 2005; 281(3):1746-54. DOI: 10.1074/jbc.M509590200. View

Tautz L, Pellecchia M, Mustelin T . Targeting the PTPome in human disease. Expert Opin Ther Targets. 2006; 10(1):157-77. DOI: 10.1517/14728222.10.1.157. View

10.

Daouti S, Li W, Qian H, Huang K, Holmgren J, Levin W . A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 2008; 68(4):1162-9. DOI: 10.1158/0008-5472.CAN-07-2349. View

11.

Han Y, Belley M, Bayly C, Colucci J, Dufresne C, Giroux A . Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. Bioorg Med Chem Lett. 2008; 18(11):3200-5. DOI: 10.1016/j.bmcl.2008.04.064. View

12.

Stephens B, Han H, Gokhale V, Von Hoff D . PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005; 4(11):1653-61. DOI: 10.1158/1535-7163.MCT-05-0248. View

13.

Tautz L, Mustelin T . Strategies for developing protein tyrosine phosphatase inhibitors. Methods. 2007; 42(3):250-60. DOI: 10.1016/j.ymeth.2007.02.014. View

14.

Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou G . Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem. 1998; 273(43):28199-207. DOI: 10.1074/jbc.273.43.28199. View

15.

Luo Y, Liang F, Zhang Z . PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry. 2009; 48(8):1838-46. PMC: 2765538. DOI: 10.1021/bi8020789. View

16.

Bessette D, Qiu D, Pallen C . PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008; 27(2):231-52. DOI: 10.1007/s10555-008-9121-3. View

17.

Bennett A, Hausdorff S, OReilly A, Freeman R, Neel B . Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell Biol. 1996; 16(3):1189-202. PMC: 231101. DOI: 10.1128/MCB.16.3.1189. View

18.

Chatterjee P, Al-Abed Y, Sherry B, Metz C . Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol. 2009; 297(5):C1294-306. PMC: 2777398. DOI: 10.1152/ajpcell.00160.2009. View

19.

DAngiolella V, Costanzo V, GOTTESMAN M, Avvedimento E, Gautier J, Grieco D . Role for cyclin-dependent kinase 2 in mitosis exit. Curr Biol. 2001; 11(15):1221-6. DOI: 10.1016/s0960-9822(01)00352-9. View

20.

Chan G, Kalaitzidis D, Usenko T, Kutok J, Yang W, Mohi M . Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 2009; 113(18):4414-24. PMC: 2676094. DOI: 10.1182/blood-2008-10-182626. View